Post-Market Clinical Follow Up Study With Navitor Valve

Inclusion Criteria:

• Patient is eligible per the current approved indication after Heart Team discussionand intended to undergo a Navitor TAVI procedure.

• The patient has been informed of the nature of the study, agrees to its provisions,and has provided written informed consent as approved by the IRB (InvestigationalReview Board)/EC (Ethics Committee) of the respective clinical site.

• The patient and the treating physician agree that the subject will return for allrequired post procedure follow up visits.

Exclusion Criteria:

• Patient is not eligible for the Navitor TAVI System per the current Instructions forUse (IFU)

• Life expectancy < 12 months from the time of informed consent due to non-cardiacco-morbid conditions.

• In the judgment of the Investigator, patient presents with a medical, social, orpsychological condition that could limit the ability or willingness to participatein the study, comply with study required testing and/or follow-up visits or thatcould impact scientific integrity of the study.

• Known contraindication for computed tomography (CT) or sensitivity to contrastmedia, which cannot be adequately premedicated.

• Inability to tolerate antiplatelet/anticoagulation therapy or nitinol alloy (nickeland titanium), which cannot be adequately premedicated.

• Currently participating in an investigational drug or device study that may confoundthe results of this study

• Anatomy that makes insertion and endovascular access to the aortic valve difficultand/or impossible